Company Profile
GSK plc Stock Price, News & Analysis
- Ticker:
- GSK
- Exchange:
- NYSE
- Sector:
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location:
- United Kingdom and listed in the U
Stock performance
52.17 USD (+1.38%)
Close
Last updated: August 6, 2026
98.3B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, GSK closed up 1.38% at $52.17. No new same-company headline was identified in the current news window.
Company overview
Global Biopharmaceutical Portfolio
GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced assets.
Specialty Medicines
Specialty Medicines are a primary growth engine for GSK. HIV therapies, oncology products, and respiratory and immunology medicines give the company a broad commercial presence across chronic and specialty-care markets.
Vaccines Franchise
GSK maintains one of the industry’s major vaccine portfolios. Shingrix, meningococcal vaccines, Arexvy, and other established products provide a large commercial base supported by global immunization infrastructure.
Expanding Late-Stage Pipeline
Recent development activity includes the acquisition of the late-stage non-small cell lung cancer assets Jideytro and neladalkib, regulatory-supporting data for Jemperli in locally advanced rectal cancer, and pivotal evidence for bepirovirsen as a potential functional cure for chronic hepatitis B.
External Innovation Strategy
GSK supplements internal research through acquisitions, licensing, and partnerships that add differentiated late-stage assets. The addition of Jideytro and neladalkib illustrates the company’s use of business development to strengthen therapeutic areas where it already has commercial and clinical infrastructure.
Future catalysts
A regulatory decision for neladalkib in non-small cell lung cancer is expected in the second half of 2026.
Regulatory progress for the Jemperli label expansion in locally advanced rectal cancer will be supported by results from the AZUR-1 study.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of GSK plc (GSK)?
GSK plc (GSK) most recently closed at 52.17 USD, a +1.38% move versus the previous session.
What is the market cap of GSK plc (GSK)?
GSK plc currently has a market capitalization of 98.3B USD on BioPharmSignal.
What does GSK plc do?
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced assets. Specialty...
On which exchange is GSK stock listed?
GSK plc (GSK) is associated with NYSE, United Kingdom and listed in the U, Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs.
What is AZUR-1?
Regulatory progress for the Jemperli label expansion in locally advanced rectal cancer will be supported by results from the AZUR-1 study.
Which conditions is GSK plc targeting with AZUR-1?
GSK plc is associated with oncology, cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does GSK plc describe recent progress with AZUR-1?
Regulatory progress for the Jemperli label expansion in locally advanced rectal cancer will be supported by results from the AZUR-1 study.
What is Global?
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines.